SNP Genotyping and Analysis Market Report 2026

The snp genotyping and analysis market size has grown exponentially in recent years. It will grow from $18.5 billion in 2025 to $22.24 billion in 2026 at a compound annual growth rate (CAGR) of 20.2%. The growth in the historic period can be attributed to declining cost of genetic testing, expansion of academic genomics research, growth in disease diagnostics, pharmaceutical r&d investment, development of microarray technologies.

The snp genotyping and analysis market size is expected to see exponential growth in the next few years. It will grow to $46.29 billion in 2030 at a compound annual growth rate (CAGR) of 20.1%. The growth in the forecast period can be attributed to growth in personalized medicine, increased use of companion diagnostics, ai-driven genomic analytics, expansion of clinical genomics, government genomics initiatives. Major trends in the forecast period include expansion of precision medicine applications, rising adoption of pharmacogenomics, increased use of cfdna and liquid biopsy, growth of high-throughput genotyping platforms, integration of ai in genetic data analysis.

The increasing burden of genetic diseases is expected to drive the growth of the SNP genotyping and analysis market in the coming years. Genetic diseases are disorders caused by abnormalities in an individual’s DNA, which may be inherited from parents or arise due to mutations during cell division. The burden of genetic diseases is rising due to greater awareness and improved diagnostic technologies, leading to more diagnoses and higher recognition of genetic disorders. SNP genotyping and analysis support genetic disease management by identifying genetic variations linked to disease risk, progression, and drug response, enabling early diagnosis and personalized treatments. For example, in February 2023, the World Health Organization, a Switzerland-based international public health agency, reported that congenital disorders caused approximately 240,000 newborn deaths worldwide within the first 28 days of life each year, along with an additional 170,000 deaths among children aged 1 month to 5 years. Therefore, the growing burden of genetic diseases is driving the growth of the SNP genotyping and analysis market.

Major companies in the SNP genotyping and analysis market are focusing on developing advanced solutions, such as large-scale low-pass whole genome sequencing for agriculture, to address challenges in molecular breeding genotyping of diploid species. Agricultural whole genome sequencing involves decoding the complete genetic material of crops or livestock to improve traits such as yield, disease resistance, and environmental adaptability. For instance, in June 2024, MGI Tech, a China-based biotechnology company, launched a highly efficient workflow solution for agricultural large-scale low-pass whole genome sequencing (low-pass WGS). The solution includes an automated full-process product portfolio covering DNA extraction, library preparation, sequencing, and SNP & InDel calling, specifically designed for molecular breeding genotyping of diploid species. It features advanced automation platforms and leverages MGI’s DNBSEQ-T7 and DNBSEQ-G400 sequencers to achieve ultra-high throughput and flexibility. The workflow also includes pig reference panels and data analysis software to enable genotyping without the need for custom database creation.

In January 2023, QIAGEN N.V., a Germany-based provider of sample and assay technologies, acquired Verogen, Inc., for an undisclosed amount. This acquisition strengthens QIAGEN’s leadership in human identification and forensics by integrating Verogen’s advanced NGS tools and bioinformatics solutions into its Sample to Insight portfolio. Verogen Inc., a US-based biotechnology company, offers SNP genotyping and analysis through its Forenseq Kintelligence kit and universal analysis software.

Major companies operating in the snp genotyping and analysis market are Roche Diagnostics GmbH, Thermo Fisher Scientific Inc., Eurofins Genomics Inc., Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Life Sciences Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., Azenta Life Sciences Inc., LGC Limited, Invitae Corporation, Oxford Nanopore Technologies Limited, Standard BioTools Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Sophia Genetics SA, Genedata AG, Genotypic Technology Private Limited, PREMIER Biosoft International.

North America was the largest region in the SNP genotyping and analysis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the snp genotyping and analysis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the snp genotyping and analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the SNP genotyping and analysis market by increasing the cost of imported sequencing instruments, consumables, and diagnostic reagents used in genetic analysis workflows. These impacts are most pronounced in research intensive regions across Asia Pacific and Europe, where laboratories rely heavily on globally sourced technologies. Rising tariff related expenses have increased operational costs and placed pressure on research budgets and testing service pricing. This has influenced procurement planning and slowed adoption of advanced genotyping platforms in some settings. However, tariffs have encouraged regional manufacturing, localized reagent production, and improved long term supply chain resilience.

The snp genotyping and analysis market research report is one of a series of new reports that provides snp genotyping and analysis market statistics, including snp genotyping and analysis industry global market size, regional shares, competitors with a snp genotyping and analysis market share, detailed snp genotyping and analysis market segments, market trends and opportunities, and any further data you may need to thrive in the snp genotyping and analysis industry. This snp genotyping and analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

SNP genotyping and analysis involves the identification and examination of single nucleotide polymorphisms - variations at a single base pair in the genome - across individuals or populations using molecular techniques such as PCR, microarrays, or sequencing. This process allows researchers to study genetic diversity, trace inheritance patterns, and understand individual differences in drug response or susceptibility to various conditions.

The main types of samples used in SNP genotyping and analysis include genomic DNA, ribonucleic acid (RNA), cell-free DNA (cfDNA), plasma samples, and whole blood. Genomic DNA represents the complete set of DNA in an organism, containing all genetic instructions necessary for its development and function. Tests are performed using technologies such as microarrays and gene chips, TaqMan allelic discrimination, SNP pyrosequencing, Applied Biosciences SNPlex, Sequenom MassArray MALDI-TOF, and others. These analyses are applied in disease diagnostics, pharmacogenomics, precision medicine, forensic science, agriculture, and livestock. End users include hospitals and clinics, research laboratories, pharmaceutical and biotechnology companies, diagnostic laboratories, and academic and government institutions.

The SNP genotyping and analysis market consists of revenues earned by entities by providing services such as DNA extraction and quality control, whole genome SNP analysis, SNP chip services, genetic association studies, and bioinformatics analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The SNP genotyping and analysis market also includes sales of genotyping platforms, genotyping assays/kits, bioinformatics software, Axiom genome-wide arrays, and bioinformatics analysis tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.